Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Precision Peptide CoPNGAF -6.25%23 Equity-to-Asset is 0.70 as of Apr. 2026, which is 75% above its 10-year median of 0.40. GuruFocus rates PNGAF with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 1,993 Consumer Packaged Goods companies, The Precision Peptide Co ranks better than 73.31% on this metric.
The Precision Peptide Co (OTCPK:PNGAF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
The Precision Peptide Co Equity-to-Asset Related Terms
The Precision Peptide Co Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, The Precision Peptide Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Precision Peptide Co Equity-to-Asset vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, The Precision Peptide Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where The Precision Peptide Co's Equity-to-Asset falls into.
The Precision Peptide Co Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
The Precision Peptide Co's Equity to Asset Ratio for the fiscal year that ended in Oct. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Precision Peptide Co (PNGAF) has a Equity-to-Asset of 0.70 as of Apr. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on The Precision Peptide Co and its competitors. This is 75% above median its historical median of 0.40. According to the industry distribution chart, The Precision Peptide Co ranks #532 out of 1993 companies in the Consumer Packaged Goods industry, placing it in the top 26.7%.
Is The Precision Peptide Co's Equity-to-Asset too high?
The Precision Peptide Co's current Equity-to-Asset of 0.70 is 75% above median its 10-year median of 0.40. The Consumer Packaged Goods industry median Equity-to-Asset is 0.55. The Precision Peptide Co's value of 0.70 is 27.3% above this industry median. Based on the distribution chart, The Precision Peptide Co ranks #532 out of 1993 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, The Precision Peptide Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does The Precision Peptide Co's Equity-to-Asset compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, The Precision Peptide Co ranks #532 out of 1993 companies for Equity-to-Asset. This puts The Precision Peptide Co in the upper half of its industry. The industry median Equity-to-Asset is 0.55. The Precision Peptide Co's value of 0.70 is 27.3% above this benchmark. While the company's 10-year median is 0.40 vs. the industry median of 0.55, The Precision Peptide Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Consumer Packaged Goods company?
The median Equity-to-Asset among Consumer Packaged Goods companies is 0.55, based on 1,993 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Precision Peptide Co's current Equity-to-Asset of 0.70 is 27.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on The Precision Peptide Co and its competitors. For the Consumer Packaged Goods industry, the median Equity-to-Asset is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Precision Peptide Co's current Equity-to-Asset is 0.70, which is 75% above median its own 10-year median of 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Precision Peptide Co stock overvalued right now?
The Precision Peptide Co (PNGAF) has a current Equity-to-Asset of 0.70. The current Equity-to-Asset is 0.70, which is 75% above median its 10-year median of 0.40 and 27.3% above the Consumer Packaged Goods industry median of 0.55. The Precision Peptide Co's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For The Precision Peptide Co (PNGAF), the current Equity-to-Asset is 0.70 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
The Precision Peptide Co Inc is a food manufacturer and distributor of nutritional supplements, functional snacks, natural foods, peptides, and natural personal care products. The company offers end-to-end services from formulation and ingredient sourcing to final packaging and fulfillment. The Company has two reportable operating segments: the manufacturing and distribution of food products in Canada and the sale and delivery of its peptide products in the United States.
23GF Score
Get the complete analysis for PNGAF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PNGAF has been successfully added to your 
